What Mesenbio does

Mesenbio is a preclinical UK biotechnology company spun out of the University of York in 2021, headquartered within the university's Department of Biology with a team of 1–10 employees. Its core technology is FT-01, a proprietary, clonal, immortalised mesenchymal stem cell line engineered to produce consistent, scalable extracellular vesicles (EVs). The platform targets a structural bottleneck in EV therapeutics — batch-to-batch variability caused by reliance on primary donor cells — and is presented as GMP-ready, with the company reporting an 84% reduction in cost of goods at commercially relevant production scales. As a platform-plus-program company, Mesenbio applies FT-01 internally to MEV-N01, a proof-of-concept regenerative EV therapy for rheumatoid arthritis delivered via intra-articular injection with a dual-action mechanism combining immune modulation and tissue repair, and externally offers FT-01 as a licensable manufacturing platform.

Mesenbio monetises FT-01 entirely through B2B enterprise channels targeting pharmaceutical and biotech companies. Four contractual models are described: platform licensing (access to FT-01 for partner therapeutic programs on negotiated royalty terms), joint development partnerships (collaborative EV therapeutic co-development), GMP-grade manufacturing services (contract EV production using FT-01), and technical consultancy/knowledge transfer. All terms are individually negotiated and pricing is not publicly disclosed. Customer segments are large pharma and biotech firms developing EV therapeutics in regenerative medicine, immunology, oncology, and CNS disorders, with academic institutions positioned as a secondary research-collaboration segment.

Operationally, Mesenbio has assembled an advisory board spanning clinical academia (Prof. John Isaacs, Newcastle University; Prof. Rose Maciewicz, University of Glasgow / ex-AstraZeneca), cell therapy industry (Dr. Panteli Theocharous, Stratus Therapeutics), and bioprocess CDMO channels (Dimor Elbers, Lonza Licensing), and is partnered with Versus Arthritis and Innovate UK. The company raised £1.4 million in January 2024 in a round co-led by DSW Ventures and NG Bio, with Innovate UK grant support, earmarked for pre-clinical work, manufacturing process development, and clinical trial preparation. To date no commercial revenue, licensing deals, or named partner transactions have been disclosed.

Name

Mesenbio

Legal name

Mesenbio

Website

https://mesenbio.net

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Mesenbio is a University of York spin-out developing FT-01, a proprietary immortalised mesenchymal stem cell platform for consistent, scalable extracellular vesicle (EV) production. It licenses the platform to pharmaceutical and biotech partners while advancing MEV-N01, a proof-of-concept regenerative EV therapy for rheumatoid arthritis.

Ownership category

akta.pro rank

Product category

Regenerative medicine / extracellular vesicle therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

akta.pro secondary industries

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Extracellular vesicle therapeutics
• Mesenchymal stem cell platform
• Regenerative medicine biotech
• Clinical-grade EV manufacturing
• Rheumatoid arthritis therapy

Headquarters

HQ city

Newyork

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Platform Licensing: Licensing FT-01 technology to pharmaceutical and biotech companies for specific therapeutic applications. Complete technology access for partners to use the FT-01 platform for their EV-based therapeutic development programs.
2. Joint Development Partnerships: Collaborative research programs in areas of mutual interest with pharma and biotech partners, contributing scientific expertise and platform capabilities to co-develop EV therapeutics.
3. Manufacturing Services: Production of GMP-grade EVs using the established FT-01 platform for partners requiring manufacturing support.
4. Technical Support and Consultancy: Knowledge transfer and ongoing scientific collaboration with partners seeking consultancy on their EV development programs.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Mesenbio develops and licenses the FT-01 platform, a proprietary immortalised mesenchymal stem cell line that enables consistent, scalable, GMP-grade extracellular vesicle (EV) production for therapeutic use. Building on this platform, the company runs MEV-N01, a preclinical regenerative EV therapy for rheumatoid arthritis delivered via intra-articular injection. Revenue is generated by licensing FT-01, partnering on co-development, and offering GMP manufacturing and technical consultancy to pharmaceutical and biotech partners.

Product overview

Mesenbio operates a platform-plus-program architecture built around FT-01, their proprietary immortalised mesenchymal stem cell line for consistent, scalable extracellular vesicle (EV) production. The FT-01 platform serves as the foundational technology enabling clinical-grade EV manufacturing, while MEV-N01 represents their lead therapeutic program applying this platform to rheumatoid arthritis treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• FT-01 Platform Proprietary, clonal, immortalised mesenchymal stem cell line that enables consistent, scalable, GMP-grade production of extracellular vesicles (EVs) for pharmaceutical and biotech partners developing regenerative, immunology, oncology, and CNS therapeutics. Sold via platform licensing, joint development, and contract GMP manufacturing.
• MEV-N01 Preclinical, proof-of-concept regenerative EV therapy for rheumatoid arthritis derived from the FT-01 platform. Targets both inflammation reduction and tissue repair via intra-articular injection, offering a minimally invasive disease-modifying approach with the potential to delay or prevent joint replacement surgery.

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered key opinion leader.

• Versus Arthritiskey opinion leaderStrategic or Co-development PartnerVersus Arthritis is mentioned as a key opinion leader alignment supporting scientific credibility and commercial potential of the FT-01 platform. The partnership represents important validation for the company's rheumatoid arthritis therapeutic program.
• University of Yorkkey opinion leaderStrategic or Co-development PartnerUniversity of York is the origin institution for Mesenbio as a spin-out company. Prof. Paul Genever serves as Chief Scientific Officer with academic credentials from the university. Research collaboration network includes disease models, clinical expertise, and regulatory guidance.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Capricor Therapeutics: Capricor is a clinical-stage biotech developing extracellular vesicle/exosome-based therapeutics (e.g., CAP-1002 for Duchenne muscular dystrophy). It is directly comparable to Mesenbio as a peer EV therapeutics company, though focused on cardiosphere-derived EVs rather than MSC-derived EVs.
• RoosterBio: RoosterBio develops and manufactures MSC (mesenchymal stem/stromal cell) products and process development tools for regenerative medicine. Comparable as a peer in scalable MSC-derived therapeutic manufacturing, though focused on the cells themselves rather than the EV products.
• ExoCoBio: ExoCoBio is a South Korea-based developer of exosome-based therapeutics and cosmetic/regenerative products derived from stem cells. Comparable as an MSC-derived EV player pursuing both therapeutic and broader regenerative applications.
• Evox Therapeutics: Evox is an Oxford-based biotech engineering extracellular vesicles for targeted delivery of nucleic acids, proteins, and small molecules across multiple therapeutic areas. It is one of the most directly comparable engineered EV platform companies to Mesenbio's FT-01.

Emerging players

• Codiak BioSciences: Codiak pioneered engineered exosome therapeutics (engEx platform) for oncology and rare diseases, and while it wound down operations, its technology and IP represent the closest precedent to a platform licensing model in EVs, making it strategically comparable to Mesenbio's playbook.

Others

• Exosome Diagnostics (a Bio-Techne brand): Exosome Diagnostics (now part of Bio-Techne) develops exosome-based liquid biopsy diagnostics. Comparable as an exosome-focused company leveraging EV biology, though primarily in diagnostics rather than therapeutics.

Regional players

• ReNeuron: ReNeuron is a UK-based clinical-stage cell therapy company developing allogeneic stem cell therapies, including for retinal disease and stroke. Comparable as a UK-headquartered regenerative medicine peer with a similar platform-plus-program structure.
• Oxford BioMedica: Oxford BioMedica is a UK-based CDMO specializing in lentiviral vector manufacturing for cell and gene therapy. Comparable as a UK-headquartered specialist CDMO serving similar pharma customers, though its modality (viral vectors) differs from EV production.

Broad incumbents

• Lonza Cell & Gene: Lonza is a global CDMO with a Cell & Gene Therapy business that includes MSC and exosome-related manufacturing capabilities. Relevant as a broad incumbent serving similar pharma customers with CDMO and licensing offerings that overlap with Mesenbio's manufacturing services and platform ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/mesenbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mesenbio